Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Major Funds Amplify Stake in Royal Gold Amid Sector Rally

Robert Sasse by Robert Sasse
December 1, 2025
in Analysis, Commodities, Gold & Precious Metals
0
Royal Gold Stock
0
SHARES
37
VIEWS
Share on FacebookShare on Twitter

A surge of institutional capital is flowing into Royal Gold, a prominent player in the precious metals streaming sector, coinciding with gold prices reaching a six-week peak. Recent regulatory filings have unveiled substantial position increases by major asset managers, with one firm boosting its holdings by over 1,000%. This aggressive accumulation by professional investors comes despite the company’s latest quarterly results missing analyst targets.

Institutional Holdings Reach Dominant Levels

The conviction of large-scale investors is unmistakable. Regulatory disclosures confirm that institutional entities are significantly expanding their equity positions in Royal Gold. The most dramatic move was executed by Neuberger Berman Group LLC, which increased its stake by a staggering 1,124% during the reporting period. The firm now holds nearly 110,000 shares, signaling strong confidence.

This activity is part of a broader trend. Other heavyweight investors, including Legal & General and American Century, have also added to their existing holdings. Collectively, institutional investors now control a substantial 83.65% of the company’s outstanding shares, indicating deep involvement from so-called “smart money.”

Gold’s Momentum Provides Strategic Tailwind

The timing of these investments aligns with a powerful rally in the precious metals market. Gold is approaching a fresh six-week high, fueled by growing market expectations that the U.S. Federal Reserve will initiate interest rate cuts in December. This environment is particularly favorable for Royal Gold’s business model. As a streaming and royalty company, it gains direct exposure to rising metal prices without bearing the operational risks and capital expenditures associated with traditional mining operations.

Should investors sell immediately? Or is it worth buying Royal Gold?

Notably, the recent quarterly figures, which fell short of profit and revenue forecasts, appear to have done little to deter these large investors. Their focus seems to be on the broader picture: a year-over-year revenue increase exceeding 30% and the company’s attractive dividend policy.

Analysts See Further Upside Potential

The fundamental and technical backdrop for Royal Gold remains positive. The share price is consolidating near its annual high, supported by the strength in gold and sustained institutional interest. Market researchers continue to see room for growth. The average price target among analysts stands at $225.40, suggesting an approximate upside potential of 12% from current levels.

A key focus for the trading sessions ahead will be whether the stock can maintain its footing above the psychologically significant $200 threshold. Should the gold rally persist leading into the Fed’s December meeting, Royal Gold may be positioned to challenge its next resistance level.

Ad

Royal Gold Stock: Buy or Sell?! New Royal Gold Analysis from March 25 delivers the answer:

The latest Royal Gold figures speak for themselves: Urgent action needed for Royal Gold investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Royal Gold: Buy or sell? Read more here...

Tags: Royal Gold
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Tilray Stock

Tilray Executes Major Share Consolidation Amid Shifting Institutional Landscape

Amazon Stock

A Surprising Alliance and Record Sales: Amazon's Strategic Moves

PayPal Stock

A Crisis of Confidence: PayPal's Leadership Exodus Overshadows Strong Fundamentals

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com